Medicus Pharma Ltd (MDCX) Q3 2026 Earnings Call Highlights: Pfizer ADC License, SkinJet SPAC ...
Medicus Pharma Ltd MDCX
$1.83
▼ -2.92%
($-0.06)
Open
$1.92
Prev Close
$1.89
Day Range
$1.72 – $2.10
52W Range
$1.70 – $127.50
Market Cap
$3.57M
Beta
-0.83
EPS (TTM)
$-1.81
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2023-10-11 |
| Shares Out. | 1,900,000 |
| Website | medicuspharma.com/ ↗ |
| Phone | 16105407515 |
| Employees | 16 |
About Medicus Pharma Ltd
Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.
Medicus Pharma Ltd is a publicly traded company under the ticker symbol MDCX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
10 analysts (2026-11-01)
📰 Latest News for MDCX
Medicus Pharma (MDCX) Q3 2026 Earnings Call Transcript
Medicus Pharma Ltd. (MDCX) Q3 2026 Earnings Call Transcript
Medicus Pharma sharpens focus on Pfizer-licensed cancer drug CD228V, trims costs in Q3
Medicus Pharma Q3 2026 Earnings Call Transcript
Medicus Pharma to Highlight Rationale for CD228V Co-Development and License Agreement
Medicus Pharma Unveils Capital Strategy Centered On Novel Cancer Pipeline
Medicus Pharma Ltd. Common Stock Q3 2026 Earnings Call Summary